News

Please see OraTaiao newsletter attached.

P3 Recovery is one of Australasia's fastest growing recovery and wellbeing communities. We combine science-backed recovery modalities with welcoming, high energy environments that help people feel better, move better and perform better in everyday life. With locations across Australia and New Zealand, and continued expansion ahead, we're on a mission to make recovery more accessible and help more people build sustainable health and wellbeing habits. At P3, recovery is a lifestyle, not a...

Raumanga Medical Centre and Rust Avenue Medical Centre have exciting opportunities for a Nurse Practitioner to join our growing, owner-operated practices. We are proud to be: Equity-focused and committed to improving health outcomes A teaching practice supporting the next generation of clinicians Cornerstone accredited, with a strong focus on quality and excellence Serving a high Māori population and working closely with our community Home to an experienced, supportive, and genuinely...

We wish to inform you of several upcoming changes: Supply issues: rosuvastatin (Rosuvastatin Viatris all strengths) ursodeoxycholic acid caps 250mg (Ursosan) temozolomide 5mg capsules (Temaccord). promethazine hydrochloride injection 25 mg per ml, 2 ml ampoule (Hospira) Change to dispensing frequency and stock available: perindopril (Coversyl) all strengths progesterone (Utrogestan) 100 mg capsule Ultraproct Ointment Dexamfetamine sulfate Tab 5 mg (Noumed) Discontinuation: Insulin...

Issue 345 - 25 June 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here. You can also access other recent issues of the digest here. If you have any queries, please email us at library@health.govt.nz Article Access For articles that aren't open access, contact...

Kia ora Pharmac has decided to fund another brand of methylphenidate, Rubifen LA, to help ease supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD). Rubifen LA will be funded from 1 October 2026. Decision to fund a new brand of methylphenidate Thank you to everyone who provided feedback during consultation. This feedback has informed our decision. If you have any questions, please contact us at enquiry@pharmac.govt.nz. Ngā mihi...